Stifel Nicolaus Boosts Cipher Pharmaceuticals (TSE:CPH) Price Target to C$17.00

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) had its target price hoisted by Stifel Nicolaus from C$16.00 to C$17.00 in a report published on Wednesday, BayStreet.CA reports. The brokerage currently has a buy rating on the stock.

Other equities analysts have also recently issued reports about the company. Leede Financial cut Cipher Pharmaceuticals from a strong-buy rating to a hold rating in a research note on Friday, September 13th. Stifel Canada upgraded shares of Cipher Pharmaceuticals from a hold rating to a strong-buy rating in a research report on Monday, August 12th.

Cipher Pharmaceuticals Price Performance

CPH opened at C$14.53 on Wednesday. The company has a debt-to-equity ratio of 0.33, a quick ratio of 2.67 and a current ratio of 11.18. Cipher Pharmaceuticals has a 1-year low of C$4.10 and a 1-year high of C$19.69. The company has a 50-day moving average of C$14.55 and a 200-day moving average of C$10.66. The company has a market capitalization of C$371.82 million, a P/E ratio of 11.81 and a beta of 1.25.

Cipher Pharmaceuticals (TSE:CPH) (NASDAQ:CPHR) last announced its quarterly earnings data on Thursday, August 8th. The company reported C$0.16 earnings per share (EPS) for the quarter, beating the consensus estimate of C$0.15 by C$0.01. The firm had revenue of C$7.26 million for the quarter, compared to analysts’ expectations of C$7.52 million. Cipher Pharmaceuticals had a return on equity of 28.43% and a net margin of 102.01%. Equities analysts expect that Cipher Pharmaceuticals will post 1.4156977 EPS for the current fiscal year.

About Cipher Pharmaceuticals

Cipher Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada. It offers Epuris (isotretinoin), an oral retinoid indicated for the treatment of severe nodular and/or inflammatory acne, acne conglobate, and recalcitrant acne; Actikerall, a topical solution indicated for the treatment of slightly palpable and/or moderately thick hyperkeratotic actinic keratosis (Grade I/II) of the face, forehead, and balding scalp; Ozanex for the topical treatment of impetigo; Vaniqa, a topical cream for the slowing of the growth of unwanted facial hair in women; Durela, an opioid analgesic for the management of moderate to moderately severe pain in adults; Brinavess for the rapid conversion of onset atrial fibriallation to sinus rhythm in adults; and Aggrastat, a reversible GP IIb/IIIa inhibitor for use in patients with Acute Coronary Syndrome.